Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 2453 for:    NMDA

Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area (MuPRaNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02443350
Recruitment Status : Unknown
Verified May 2015 by Jia Wei Wang,MD, Beijing Tongren Hospital.
Recruitment status was:  Recruiting
First Posted : May 13, 2015
Last Update Posted : May 13, 2015
Sponsor:
Information provided by (Responsible Party):
Jia Wei Wang,MD, Beijing Tongren Hospital

Brief Summary:
Anti N-methyl-D-aspartate receptor encephalitis is an autoimmune encephalitis,found in recent years,producing the specific IgG antibody induced by the NMDA receptors.It is the most common curable disease among the non infectious-autoimmune encephalitis,usually has been misdiagnosed as other causes of encephalitis.Our previous study found that there are differences between the Chinese and the foreign in anti-NMDA receptor encephalitis such as the sex ratio, the rate of combined tumor and clinical manifestations.As a new found disease,the incidence rate has been underestimated.Therefore,to establish the Registry Research Database for Chinese group of anti-NMDA receptor encephalitis is imminent.This study will combine Beijing area's hospitals and foreign experts,depending on multicenter, prospective and registry method,to understand the incidence in Beijing area,to summarize and analyze the clinical data of patients.So,there will make a solid foundation for the subsequent Beijing area detection platform and other research.

Condition or disease
Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 24 Months
Study Start Date : June 2014
Estimated Primary Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Encephalitis




Primary Outcome Measures :
  1. death [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The unexplained encephalitis patients in Beijing area
Criteria

Inclusion Criteria:

  • Older than 6 months.
  • Encephalopathy symptoms (change of mental state and consciousness level) persist for more than 24 hours;
  • At least one or more clinical features of the followings: fever, epilepsy, focal neurological deficiency symptoms, changes in CSF(cerebrospinal fluid inflammatory), changes in EEG (electroencephalogram), radiographic abnormalities;
  • Clinical suspected encephalitis, but conventional detected methods cannot make etiology clear

Exclusion Criteria:

  • Infants less than 6 months;
  • The metabolic encephalopathy;
  • Infectious encephalitis with clinically clear pathogen, referring the specific pathogenic microorganisms, including: bacteria, virus, fungus, parasite, spirochete and so on;
  • Non-infectious encephalitis with clinically clear diagnosis, including: multiple sclerosis, optic neuromyelitis, acute disseminated encephalomyelitis and so on.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02443350


Contacts
Layout table for location contacts
Contact: Jia Wei Wang, M.D (86)010-58268857 wangjwcq@163.com

Locations
Layout table for location information
China, Beijing
Beijing Tongren Hospital,Capital Medical Universiy Recruiting
Beijing, Beijing, China, 100730
Contact: Jia Wei Wang, M.D    (86)15910785840    wangjwcq@163.com   
Sponsors and Collaborators
Jia Wei Wang,MD

Additional Information:

Layout table for additonal information
Responsible Party: Jia Wei Wang,MD, M.D.;The head of Department of Neurology and Medical Research Center, Beijing Tongren Hospital
ClinicalTrials.gov Identifier: NCT02443350     History of Changes
Other Study ID Numbers: CH 201411101
First Posted: May 13, 2015    Key Record Dates
Last Update Posted: May 13, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Encephalitis
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Paraneoplastic Syndromes, Nervous System
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Paraneoplastic Syndromes
Neurodegenerative Diseases
Autoimmune Diseases of the Nervous System
Autoimmune Diseases
Immune System Diseases